GHRP-2
GHRP-2 (Pralmorelin)
A second-generation growth hormone releasing peptide with potent GH stimulation and some cortisol and prolactin elevation.
GHRP-2 is not approved by the FDA for human use. It is sold strictly for research purposes only and is not intended for human consumption, diagnosis, treatment, or prevention of any disease or condition. Purchase and use is entirely at your own risk.
Sourcing for research purposes?
View at Ascension Peptides →What it is
GHRP-2 is a synthetic hexapeptide and second-generation GHRH receptor agonist. It was one of the most widely studied GHRPs in clinical research, with a number of completed human trials. Its potency is notably higher than Ipamorelin, though it comes with a more pronounced cortisol and prolactin response.
It stimulates GH through the ghrelin receptor (GHS-R1a) and has been used as a research tool to study GH secretion dynamics.
What research shows
- Potent, dose-dependent GH release in human trials
- Moderate cortisol and prolactin elevation — greater than Ipamorelin, less than Hexarelin
- IGF-1 elevation with sustained use
- Improved body composition signals in some trials
- Does not produce the strong hunger response seen with GHRP-6
What remains unknown
- Optimal long-term protocols for body composition in healthy adults
- Degree to which cortisol elevation at typical doses is clinically meaningful
- Comparative efficacy vs. Ipamorelin for body composition outcomes
Administration basics
Common use cases
GH optimization, body composition, recovery. Often paired with CJC-1295.
Half-life
~1 hour.
Administration
Subcutaneous injection. Typically dosed 2–3x daily on an empty stomach.
Source this compound
Looking for GHRP-2?
Ascension Peptides is a third-party research compound vendor. We link to them as an affiliate — if you purchase through our link we may earn a commission at no cost to you. All compounds are sold for research purposes only and are not intended for human use.
View at Ascension PeptidesResearch Protocols & Common Usage
Doses used in research
- Research studies have used 100–300mcg per injection, administered 2–3 times daily
- Community protocols commonly follow similar dosing on an empty stomach
Administration routes studied
Typical protocol duration
Research studies have run 4–12 weeks. Community protocols commonly report 8–12 week cycles.
Common stacking protocols
- GHRP-2 + CJC-1295 — GHRP/GHRH combination for amplified GH release
- GHRP-2 + Sermorelin — alternative GHRP/GHRH pairing
Contraindications & combinations to avoid
- Active cancer or cancer history
- Elevated cortisol or cortisol-sensitive conditions — GHRP-2 elevates cortisol more than Ipamorelin
- Elevated prolactin or prolactin-sensitive conditions
- Should not be combined with Ipamorelin — redundant GHRP mechanism
Dosing information reflects doses used in published research and commonly reported community protocols only. This is not a personal recommendation. These compounds are not FDA-approved for human use in the contexts described. Consult a qualified healthcare provider before starting any protocol.
Considering stacking?
See the stacking guide for common combinations with GHRP-2 and what to avoid.
Track your GHRP-2 protocol
Log your experience, track outcomes over time, and get AI-powered interpretation of your results after 14 days of data. Private, $14.99/month.
Start trackingGet research updates
We'll notify you when we update the GHRP-2 page or publish related research.
More in the library
Community Reviews
Reviews reflect individual user experiences with research compounds and are not medical advice. Results vary. These compounds are not FDA approved for human use. Peptelligent does not verify reported experiences.
Write a Review
No reviews yet. Be the first to share your experience.